Trial Profile
Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms Perseas
- Sponsors Roche
- 15 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Aug 2012 Actual end date changed from 1 Mar 2010 to 1 May 2009 as reported by ClinicalTrials.gov.
- 15 Aug 2012 Planned end date changed from 1 Sep 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.